Navigation Links
Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
Date:12/30/2011

AMSTERDAM, December 30, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the Company has raised € 2.5 million in new equity by means of a private placement to three of its existing shareholders: Forbion Capital Partners, Gilde Healthcare Partners and Advent Venture Partners.

Under the terms of the transaction, AMT has agreed to issue 7,352,938 new shares at a price of € 0.34 per share, being the closing price on December 29, 2011, when the shares were placed. The proceeds of this issue will provide additional flexibility to further explore its strategic options to secure the financial stability of the Company. The proceeds do not eliminate the Company's negative equity position, which will continue after completion of the equity raising, which is expected to take place on or around January 4, 2012, and the Company's financial prospects remain as described in the announcement of December 15, 2011.

As a result of the private placement, the Company's issued share capital will amount to 31,051,454 shares.

Pursuant to the Financial Supervision Act (Wet op het financieel toezicht) there is no obligation to publish a prospectus approved by the Netherlands Authority for the Financial Markets (Autoriteit Financiele Markten) in relation to the equity raising or the admission of the new shares to trading on NYSE Euronext in Amsterdam. The Netherlands Authority for the Financial Markets does not supervise the equity raising or the admission of the new shares to trading on NYSE Euronext in Amsterdam.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the del
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amsterdam Molecular Therapeutics Announces Negative Equity Position
2. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
3. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
4. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
5. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
7. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
11. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... February 27, 2015 Immunovaccine Inc. ... immunotherapy company, today announced that the U.S. Food ... Fast Track designation and Phase I clinical trials ... with the mutual co-development agreement signed with Gilead ... Track designation for the DPX-Survivac. , “We have ...
(Date:2/27/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... today announced that it will be presenting at CALBIO ... 2 nd at 3pm PST. Patrick Lucy, chief business ... the current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and ...
(Date:2/27/2015)...  Steep Hill, the industry leader in cannabis testing ... open a full service medical cannabis quality assurance laboratory ... advanced scientific tools and methodology to the state, for ... currently the only laboratory licensed by the New Mexico ... in order to meet the recently adopted regulatory requirements ...
(Date:2/26/2015)... N.J. , Feb. 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript,s trade secrets, and that it improperly ... entered an order denying motions for judgment notwithstanding the ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... 14 When world political leaders are being transported ... Conference in December 2009, environmentally friendly fuel will power ... co-operation between Danisco,s biotech division Genencor, Inbicon, Novozymes and ... for 40 of the cars that the Danish Foreign ...
... , , ... biotechnology company delivering breakthrough therapies in central nervous system ... the efficacy of the ketogenic compound AC-1202 (Axona(TM)) in ... completed double-blind, placebo-controlled trial in patients with mild-to-moderate Alzheimer,s ...
... ... Lives by Ensuring Quality Care , ... San Francisco, CA (PRWEB) July 14, 2009 -- Quantros, a leading ... will continue its partnership with USC University Hospital and USC Kenneth Norris, Jr. Cancer ...
Cached Biology Technology:Politicians to Drive on Straw-Based Bioethanol at the Climate Change Conference 2Politicians to Drive on Straw-Based Bioethanol at the Climate Change Conference 3Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease 2Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease 3Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease 4USC Hospitals Extend Relationship With Quantros to Manage Compliance and Risk 2USC Hospitals Extend Relationship With Quantros to Manage Compliance and Risk 3
(Date:1/22/2015)... TORONTO , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the ... announced the launch of its new website design. ... in its infancy", says Peter O,Neill , founder and ... ever, the industry needs involvement from the key players on ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... including technology and tech stocks, releases video from the CES ... and security consultant Apollo Robbins . Apollo ... the Wocket™ biometric smart wallet, a product of NXT-ID, Inc. ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... how can we find out about the future dangers it ... the Earths climate for several hundred thousand years, complete with ... to the lab for analysis. Incredibly, this record exists, in ... European Science Foundation programme has a key role in deciphering ...
... about the separation of producers and consumers in our ... research funded by Economic and Social Research Council (ESRC) ... consumers and producers involved in alternative food networks, which ... gardens and farm animal adoption. Through participation, consumers ...
... recent findings that reveal some of the factors underlying the aging ... paper, Stem Cell Aging is Controlled both Intrinsically and Extrinsically in ... Cell Stem Cell. Lei Pan, Predoctoral Researcher, and Ting Xie, Ph.D., ... It is widely postulated that ...
Cached Biology News:European lead in reading past climates from ice cores 2European lead in reading past climates from ice cores 3Alternative food networks connect ethical producers and consumers and can lead to healthier eating 2Stowers Institute's Xie Lab demonstrates dual intrinsic and extrinsic control of stem cell aging 2
Economical and manually filled LN2 vacuum insulated storage container offers high capacity and low nitrogen consumption while offering convenient storage of samples....
... Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV ... be used in cDNA synthesis with long messenger ... of the pol gene of M-MLV and consists ... of 71kDa. The RNase H activity of M-MLV ...
... 8-iso-13,14-dihydro-15-keto Prostaglandin F2α (8-iso-13,14-dihydro-15-keto PGF2α) ... 8-isoprostane (8-iso PGF2α), in rabbits, monkeys ... PG-like product of non-specific lipid peroxidation. ... infused 8-isoprostane is converted primarily to ...
... Cell Cultures (ECACC) in conjunction with the ... of England, Bristol, UK, have produced standardised ... HER2, oestrogen and progresterone receptor assays. The ... formalin fixed, breast cancer cell lines; MDA-MD-361, ...
Biology Products: